Precision Medicine in Type 2 Diabetes Mellitus: Advances in Continuous Assessment, Subclassification, Personalized Therapies, and Disease Remission: A Comprehensive Review.

Precision medicine in type 2 diabetes mellitus (T2DM) shifts from uniform treatment to individualized strategies addressing genetic, metabolic, environmental, and clinical heterogeneity. Key pillars include continuous glucose monitoring (CGM) for dynamic glycemic insights, subtype stratification (e.g., severe insulin-resistant diabetes [SIRD], severe insulin-deficient diabetes [SIDD]), pharmacogenomics-guided therapy, and interventions enabling remission. CGM improves time in range, reduces variability, and supports tailored adjustments beyond HbA1c limitations. Clustering identifies differential complication risks and drug responses, favoring SGLT2 inhibitors in SIRD or GLP- receptor agonists in SIDD. Remission sustained normoglycemia without medication

Precision medicine; Type 2 diabetes mellitus; Continuous glucose monitoring

1. Ajjan, R.A., Seidu, S. and Riveline, J.P. (2024) “Perspective of Continuous Glucose Monitoring-Based Interventions at the Various Stages of Type 2 Diabetes,” Diabetes Therapy, 15(8), pp. 1657–1672. Available at: https://doi.org/10.1007/s13300-024-01607-5. [Google Scholar] [Crossref]

2. Arias-Marroquín, A.T. et al. (2024) “Personalized Versus Non-personalized Nutritional Recommendations/Interventions for Type 2 Diabetes Mellitus Remission: A Narrative Review,” Diabetes Therapy, 15(4), pp. 749–761. Available at: https://doi.org/10.1007/s13300-024-01545-2. [Google Scholar] [Crossref]

3. Bonnefond, A. and Froguel, P. (2021) “Clustering for a better prediction of type 2 diabetes mellitus,” Nature Reviews Endocrinology, 17(4), pp. 193–194. Available at: https://doi.org/10.1038/s41574-021-00475-4 [Google Scholar] [Crossref]

4. Chang, T. (2023) “Mechanisms and the strategy for remission of type 2 diabetes mellitus,” Journal of Diabetes Investigation, 14(3), pp. 351–353. Available at: https://doi.org/10.1111/jdi.13948. [Google Scholar] [Crossref]

5. Edgar, M. (2025) “Artificial Intelligence in Precision Diabetes Management: Towards Personalized andEquitable Care,” NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY, 6(3), pp. 75–81. Available at: https://doi.org/10.59298/nijpp/2025/637581. [Google Scholar] [Crossref]

6. Franks, P.W. and Sargent, J.L. (2024) “Diabetes and obesity: leveraging heterogeneity for precision medicine,” European Heart Journal, 45(48), pp. 5146–5155. Available at: https://doi.org/10.1093/eurheartj/ehae746. [Google Scholar] [Crossref]

7. Ghosh, K. et al. (2025) “Artificial Intelligence in Personalized Medicine for Diabetes Mellitus: A Narrative Review,” Cureus [Preprint]. Available at: https://doi.org/10.7759/cureus.91520. [Google Scholar] [Crossref]

8. Goyal Mehra, C., Raymond, A.M. and Prabhu, R. (2022) “A personalized multi-interventional approach focusing on customized nutrition, progressive fitness, and lifestyle modification resulted in the reduction of HbA1c, fasting blood sugar and weight in type 2 diabetes: a retrospective study,” BMC Endocrine Disorders, 22(1). Available at: https://doi.org/10.1186/s12902-022-01212-2. [Google Scholar] [Crossref]

9. Javed, A. et al. (2024) “Advances in Personalized Medicine and Genomics for Diabetes Type-2 Management Towards Precision Health,” DEVELOPMENTAL MEDICO-LIFE-SCIENCES, 1(6), pp. 25–30. Available at: https://doi.org/10.69750/dmls.01.06.058. [Google Scholar] [Crossref]

10. Kalra, S. et al. (2021) “Quantifying Remission Probability in Type 2 Diabetes Mellitus,” Clinics and Practice, 11(4), pp. 850–859. Available at: https://doi.org/10.3390/clinpract11040100. [Google Scholar] [Crossref]

11. Kanorskii, S.G. (2022) “Reversion and remission are promising targets for patients with type 2 diabetes mellitus,” South Russian Journal of Therapeutic Practice, 3(3), pp. 7–16. Available at: https://doi.org/10.21886/2712-8156-2022-3-3-7-16. [Google Scholar] [Crossref]

12. Kuss, O. et al. (2023) “How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials,” Diabetologia, 66(9), pp. 1622–1632. Available at: https://doi.org/10.1007/s00125-023-05951-2. [Google Scholar] [Crossref]

13. Milla-Amekor, E. and Ewusie, E.A. (2023) “Advances in Precision Medicine Approaches for Type 2 Diabetes Management: A Comprehensive Review,” Asian Journal of Research in Medical and Pharmaceutical Sciences, 12(3), pp. 46–58. Available at: https://doi.org/10.9734/ajrimps/2023/v12i3220. [Google Scholar] [Crossref]

14. Misra, S. et al. (2023) “Precision subclassification of type 2 diabetes: a systematic review,” Communications Medicine, 3(1). Available at: https://doi.org/10.1038/s43856-023-00360-3. [Google Scholar] [Crossref]

15. Nambiar, M. et al. (2024) “A drug mix and dose decision algorithm for individualized type 2 diabetes management,” npj Digital Medicine, 7(1). Available at: https://doi.org/10.1038/s41746-024-01230-5. [Google Scholar] [Crossref]

16. Oriot, P. et al. (2024) “Diabète de type 2: vers un contrôle optimal grâce au suivi continu du glucose?,” Revue Médicale Suisse, 20(884), pp. 1504–1508. Available at: https://doi.org/10.53738/revmed.2024.20.884.1504. [Google Scholar] [Crossref]

17. Riley, R.D. et al. (2021) “Penalization and shrinkage methods produced unreliable clinical prediction models especially when sample size was small,” Journal of Clinical Epidemiology, 132, pp. 88–96. Available at: https://doi.org/10.1016/j.jclinepi.2020.12.005. [Google Scholar] [Crossref]

18. Shamanna, P. et al. (2021) “Type 2 diabetes reversal with digital twin technology-enabled precision nutrition and staging of reversal: a retrospective cohort study,” Clinical Diabetes and Endocrinology, 7(1). Available at: https://doi.org/10.1186/s40842-021-00134-7. [Google Scholar] [Crossref]

19. Shields, B.M. et al. (2022) “Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study,” Nature Medicine, 29(2), pp. 376–383. Available at: https://doi.org/10.1038/s41591-022-02120-7. [Google Scholar] [Crossref]

20. Son, H., Moon, S.-J. and Cho, Y.M. (2025). The Expanding Role of Continuous Glucose Monitoring in the Management and Prevention of Type 2 Diabetes. Diabetes Therapy. doi:https://doi.org/10.1007/s13300-02501830-8. [Google Scholar] [Crossref]

21. Tan, Y.Y. et al. (2024) “Effectiveness of continuous glucose monitoring in patient management of Type 2 Diabetes Mellitus: an umbrella review of systematic reviews from 2011 to 2024,” Archives of Public Health, 82(1). Available at: https://doi.org/10.1186/s13690-024-01459-2. [Google Scholar] [Crossref]

22. Tian, X. et al. (2025) “The research progress and future directions in the pathophysiological mechanisms of type 2 diabetes mellitus from the perspective of precision medicine,” Frontiers in Medicine, 12. Available at: https://doi.org/10.3389/fmed.2025.1555077. [Google Scholar] [Crossref]

23. Tian, X. et al. (2025) “New discoveries in therapeutic targets and drug development pathways for type 2 diabetes mellitus under the guidance of precision medicine,” European Journal of Medical Research, 30(1). Available at: https://doi.org/10.1186/s40001-025-02682-5. [Google Scholar] [Crossref]

24. Venkatachalapathy, P. et al. (2021) “Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: [Google Scholar] [Crossref]

25. Potential Implications for Clinical Practice,” Pharmacogenomics and Personalized Medicine, Volume 14, pp. 1441–1455. Available at: https://doi.org/10.2147/pgpm.s329787. [Google Scholar] [Crossref]

26. Wang, S. et al. (2026) “Research progress in precision medicine for type 2 diabetes based on the GLP-1,” Frontiers in Endocrinology, 16. Available at: https://doi.org/10.3389/fendo.2025.1721842. [Google Scholar] [Crossref]

27. Wei, R. and Colón-Franco, J.M. (2021) “Subclassification of Type 2 Diabetes Paves the Way for Personalized Outcome Prediction and Patient Management,” Clinical Chemistry, 67(4), pp. 701–701. Available at: https://doi.org/10.1093/clinchem/hvab003. [Google Scholar] [Crossref]

• A Machine Learning Model for Predicting the Risk of Developing Diabetes - T2DM Using Real-World Data from Kilifi, Kenya
• AI-Powered Facial Recognition Attendance System Using Deep Learning and Computer Vision
• A Comprehensive Review on Brain Tumour Segmentation Using Deep Learning Approach
• A Scalable Retrieval-Augmented Generation Pipeline for Domain-Specific Knowledge Applications
• Predictive Maintenance in Semiconductor Manufacturing Using Machine Learning on Imbalanced Dataset